VIYASH259.00

Viyash Scientific Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSYATHARTHTHYROCARESUPRIYASTARSPARCSHILPAMEDRUBICONMcap ₹11,314 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
VIYASH
FY26
AARTIDRUGS
FY26
YATHARTH
FY26
THYROCARE
FY26
Peer
Median
Valuation — at last close
P/E63.33×20.46×53.91×54.33×53.91× +17%
P/B3.63×2.57×5.23×15.15×5.23× -31%
EV/EBITDA17.62×14.74×32.47×33.17×32.47× -46%
Market Cap₹11,314 Cr₹3,988 Cr₹9,453 Cr₹8,882 Cr₹8,882 Cr +27%
Growth
Revenue CAGR 3Y34.02%-1.89%48.11%16.33%16.33% +108%
Revenue CAGR 5Y20.23%3.55%10.88%7.21% +180%
Net Income CAGR 3Y5.43%38.45%36.27%36.27%
Revenue YoY (latest Q)114.39%19.01%52.33%24.34%24.34% +370%
Net Income YoY (latest Q)351.28%-7.12%8.05%34.06%8.05% +4264%
Profitability
EBITDA Margin19.08%12.05%24.20%31.61%24.20% -21%
Net Income Margin6.57%7.60%14.11%19.64%14.11% -53%
Return on Common Equity5.69%12.58%9.42%27.82%12.58% -55%
Return on Capital Employed11.38%12.80%9.74%31.92%12.80% -11%
Return on Assets4.85%6.92%7.46%21.79%7.46% -35%
Credit & Quality
Total Debt/Equity0.14×0.37×0.14×0.00×0.14× +0%
Interest Coverage6.05×7.19×31.26×72.66×31.26× -81%
Scale — latest FY
Revenue / Total Income₹3,420 Cr₹2,565 Cr₹1,207 Cr₹829 Cr₹1,207 Cr +183%
Net Income₹225 Cr₹195 Cr₹170 Cr₹163 Cr₹170 Cr +32%
Total Assets₹4,628 Cr₹2,815 Cr₹2,282 Cr₹747 Cr₹2,282 Cr +103%
EPS₹4.09₹21.36₹18.2₹10.27₹18.2 -78%
Book Value per Share₹71.3₹169.74₹187.55₹36.82₹169.74 -58%
◆ best value in the comp set per metric · Δ = subject vs median of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.